Former Food and Drug Administration (FDA) commissioner Scott Gottlieb said Johnson & Johnson’s new single-dose coronavirus vaccine “looks like a good profile for a vaccine.”
“All in all it looks like a good profile for a vaccine,” Gottlieb told CNBC’s “Squawk Box” on Thursday after initial data showed promising results for the Johnson & Johnson vaccine. “It’s an indication that we’ll probably have a third participant here.”
“All in all it looks like a good profile for a vaccine,” he says @ScottGottliebMD on the first data from the Johnson & Johnson single-dose COVID-19 vaccine. “It’s an indication that we’ll probably have a third participant here.” pic.twitter.com/oFzLQ0PgHV
– Squawk Box (@SquawkCNBC) January 14, 2021
Gottlieb is a board member of Pfizer, which has produced one of two vaccines that have already received emergency authorization from the FDA.
The results of the initial phase trials of the Johnson & Johnson vaccine were published Wednesday in The New England Journal of Medicine. That he showed that all trial participants had neutralizing antibodies in their system after 57 days.
The Johnson & Johnson vaccine would allow more vaccines to be dispersed and would require only one vaccine, while the current Pfizer and Moderna COVID-19 vaccines require two.
The company says more results on the vaccine could be obtained as early as the end of January. The vaccine was found to have common side effects, such as headache and fatigue.
There were plans for the company to have 12 million doses by the end of February, but manufacturing problems could delay them until April.
Vaccines are currently being administered at a slower rate than expected due to the strict guidelines of who can receive them. Officials expect the guidelines to relax in the coming weeks as the number of people receiving the vaccine will increase.